Pancreatic beta-cells: From generation to regeneration

Patrick Collombata,b, Xiaobo Xuc,d,e, Harry Heimbergc,d,e,*, Ahmed Mansouri c,f,g,**

a Inserm U636, Diabetes Genetics Team, FR-06108, Nice, France
b Université de Nice Sophia-Antipolis, FR-06108, Nice, France
c Beta-cell Biology Consortium, 2213 Garland Avenue, 9465 MRB IV, Nashville, TN 37233-0494, USA
d JDRF Center for Beta-cell Therapy in Diabetes, Laarbeeklaan 103, B-1090 Brussels, Belgium
e Diabetes Research Center, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium
f Max-Planck Institute for Biophysical Chemistry, Department of Molecular Cell Biology, Am Fassberg, D-37077 Göttingen, Germany
g Department of Clinical Neurophysiology, University of Göttingen, Robert-Koch Strasse 40, D-37075 Göttingen, Germany

Abstract

The pancreas is composed of two main compartments consisting of endocrine and exocrine tissues. The majority of the organ is exocrine and responsible for the synthesis of digestive enzymes and for their transport via an intricate ductal system into the duodenum. The endocrine tissue represents less than 2% of the organ and is organized into functional units called islets of Langerhans, comprising alpha-, beta-, delta-, epsilon- and pancreatic polypeptide (PP)-cells, producing the hormones glucagon, insulin, somatostatin, ghrelin and pancreatic polypeptide (PP), respectively. Insulin-producing beta-cells play a central role in the control of the glucose homeostasis. Accordingly, absolute or relative deficiency in beta-cells may ultimately lead to type 1 and/or type 2 diabetes, respectively. One major goal of diabetes research is therefore to understand the molecular mechanisms controlling the development of beta-cells during pancreas morphogenesis, but also those underlying the regeneration of adult injured pancreas, and assess their significance for future cell-based therapy. In this review, we will therefore present new insights into beta-cell development with focus on beta-cell regeneration.

1. Introduction

Although insulin supplementation allows a reasonable control of blood sugar levels, diabetic patients still suffer from long-term side effects of blood glucose variations, too often resulting in severe alterations of various organ functions. Transplantation of islets isolated from the pancreases of organ donors alleviates insulin-dependence in type 1 diabetes patients, providing strong support to stem cell-based therapy. It is obvious that, due to the islet shortage to suffice the need for transplantation, alternative cell sources have to be explored. At first glance, human embryonic stem (h-ES) cells and induced pluripotent stem cells (iPS) potentially may represent an unlimited source for generating beta-cells in vitro. However, although several straightforward protocols were established, including procedures using chemical compounds, both the efficiency of in vitro programming and the function of h-ES-derived beta-cells remain unsatisfactory. Besides, safety concerns due to inherent risks of teratoma formation originating from residual stem cells remain a major hurdle [1–3].
It is now accepted that in various experimental animal models of injury to the (endocrine) pancreas, such as partial pancreatectomy (PPX), partial duct ligation (PDL), and chemically- or genetically-induced beta-cell destruction, [4-10], islet cells actively regenerate. It is therefore of fundamental interest to consider the molecular mechanisms that control such regenerative processes to putatively open new avenues for an improved treatment of diabetes. The expansion of the beta-cell mass during early postnatal life, pregnancy, as well as in the pancreas of animal models for which beta-cells were genetically ablated, has been mainly attributed to beta-cell proliferation [7,11,12]. Despite these findings, it was demonstrated that beta-cells may also arise from alternative cell subtypes, such as duct-lining or acinar cells [13], as observed during embryonic development. Indeed, several studies in various animal and transgenic models support a process of duct-lining cell-derived beta-cell neogenesis [4,14-22]. However, as we will discuss thereafter, while replication of preexisting beta-cells has been established as a major component of the expansion of the beta-cell mass in normal and injured pancreas, the existence of duct-derived progenitor cells is still controversially discussed [23-25]. Finally, intra-islet precursor cells promoting beta-cell neogenesis have been also suggested [26-28].

3. Expansion of the beta-cell mass through self-replication

Glucose-mediated insulin secretion is required for the proper control of glucose homeostasis. Interestingly, during pregnancy [11] or in obese individuals [44], a beta-cell mass expansion was outlined to compensate for the increased needs. Although several molecular mechanisms promoting adaptation of the functional beta-cell mass are under discussion, self-duplication of preexisting beta-cells unquestionably represent an important process to increase islet size. Accordingly, Cre recombinase-mediated lineage tracing analyses provided compelling evidences for beta-cell replication as the main source of beta-cell neogenesis under normal physiological conditions, but also following 70% PPX [45]. Another in vivo pulse-chase study, supplemented by a clonal analysis of dividing beta-cells, supported a model where insulin-expressing cells equally participate to the replication-mediated expansion of the beta-cell mass [12]. In addition, using a novel DNA analog-based lineage tracing approach, it was found that only beta-cells contribute to the beta-cell regeneration occurring under normal physiological conditions, following 50% PPX or treatment with the GLP-1 agonist Exendin-4, and during pregnancy, underscoring the importance of replication to sustain the beta-cell turn-over [46]. These findings were confirmed by studies in transgenic mice with beta-cell depletion induced by tetracycline-controlled diphertheria toxin expression or by c-myc activated overexpression leading to beta-cell apoptosis [7,47].

In rodents, beta-cell replication appears to follow an age-dependent process for which the beta-cell mass expansion observed next to pancreas injury seems limited to young animals [48,49]. Accordingly, the proliferation rate of insulin-producing cells was found extremely reduced in 1-year old mice [49], with a Ki67 proliferation index significantly decreased in islets of 94-week old animals as compared to their 20-week old counterparts [50]. Furthermore, a clear decline in islet proliferation capability upon 90% PPX was also associated with age in rats [51].

Beta-cell replication obviously requires the activity of cell cycle regulators (for review see [52-54]). Accordingly, cyclin D2-deficient mice exhibit smaller islets, a dramatically reduced beta-cell mass, and compromised beta-cell proliferation capabilities [55,56]. While the lack of Cdk4 activity results in diabetes, the expression of a constitutively active form of Cdk4 is accompanied by beta-cell hyperplasia [57-59]. Moreover, virus-mediated overexpression of Cdk4 in human islets also induces beta-cell proliferation [52,58,60]. Similarly, the adenovirus-mediated ectopic expression of E2F1, together with protein kinase B (Akt), in primary beta-cells, results in an increase in the absolute cell number provoked by an induction of proliferation and a concomitant inhibition of cell death [61]. On the other hand, the in vivo conditional overexpression of E2F1 in beta-cells stimulates their proliferation, but not sufficiently enough to increase the beta-cell mass. However, increased insulin contents and glucose-mediated insulin release were noticed and associated to protection against STZ (streptozotocin)-induced diabetes [61].

The diminished proliferation ability in aging mice was recently correlated with an increased expression of the cell cycle inhibitor p16INK4a in older animals [62-64]. Accordingly, the loss of p16INK4a activity in mutant mice results in improved regeneration capabilities in islets of older animals following chemical ablation of beta-cells using streptozotocin (STZ), while the overexpression of
p16\(^{INK4a}\) is accompanied by diminished islet proliferation [62]. Moreover, the propensity of beta-cells to multiply in younger animals strongly correlates with the expression levels of Bmi1 and Ezh2, two polycomb proteins that control the Ink4a/Arf locus through modulation of histone modifications [65,66]. Hence, Bmi-1-deficient young mice display increased expression of p16\(^{INK4a}\) and thereby lose their capacity to expand their beta-cell mass in response to exendin-4 [63]. Similarly, in the absence of Ezh2, insulin-producing beta-cells exhibit reduced proliferation rates and mutant mice suffer from mild diabetes [66]. Interestingly, MLL, a member of trithorax TrxG protein family, was found associated to the activation of the Ink4a/Arf locus [65]. Menin, a factor encoded by the men1 locus, recruits MLL to the p27kip1 and p18ink4c promoters [67] and thereby modulates pancreatic islet growth by inducing histone methylation and activating the transcription of cell cycle inhibitors [68]. These findings underscore the role of epigenetic control of the beta-cell mass expansion during life span. Finally, it is worth noticing that other signaling pathways and factors, such as STAT5, growth hormones, prolactin and FoxM1 also play a role in beta-cell proliferation during pregnancy [11,30,65].

4. Do facultative stem cells exist in the pancreas?

Recent studies indicate that adult pancreatic cells are more “plastic” than hitherto assumed, and provide evidence for islet neogenesis in several animal models. One attractive hypothesis favors injury-induced activation of facultative stem/progenitor cells to expand the beta-cell mass [4,14,69,70]. Differentiation of facultative stem/progenitor cells might involve recapitulation of the program that controls the embryogenesis of the endocrine pancreas, including re-expression of the proendocrine factor Ngn3. As a common denominator to these reports, the ductal compartment seemingly represents the site where stem/progenitor cells at least transiently reside [4,16–22]. Robust injury using partial pancreatic duct ligation created the appropriate microenvironment to unambiguously demonstrate the existence of multipotent endocrine progenitors in the adult mouse pancreas [19]. In this model, at least part of the embryonic endocrine program is reinitiated leading to reactivation of Ngn3 in a subset of Pdx1+ cells lining the duct. Ngn3-positive cells isolated from adult duct-ligated pancreas gave rise to the four main endocrine cell subtypes when implanted in pancreatic grafts of embryonic mice that were null mutant for Ngn3 and thus incapable of producing endogenous endocrine cells. Remarkably, the Ngn3\(^{-/-}\) embryonic pancreata explants engrafted with adult Ngn3\(^{+}\) cells were glucose responsive and the newly formed beta-cells intensely proliferated [19]. Lineage tracing experiments using the human carbon anhydrase II (CAII) promoter to drive the expression of CAII in the duct was not noticed for Hnf1b-marked cells following PDL- or alloxan/EGF/gastrin-induced injuries [23,25]. Furthermore, no contribution of acinar and of duct cells to endocrine cell genesis in the early postnatal period was observed by conditional lineage tracing of Muc1\(^{+}\) cells [24]. It remains to be determined whether, in the injured pancreas, Muc1-labeled cells are involved in beta-cell regeneration.

It needs to be mentioned that cre recombinase-mediated lineage tracing strongly depends on the efficiency of recombination and that never all duct cells are labeled, increasing the chance to overlook rare stem cells residing in the duct epithelium or acinar cell compartment (see also [77]). Ngn3\(^{+}\) cells were clearly detected in the duct of mice subjected to PDL, or with ectopic Pax4 expression in alpha-cells [19,21].

Besides the ductal lining, intra-islet precursor cells as well as acinar cells were suggested to contribute to beta-cell neogenesis [18,26,28,70,78,79]. In mice treated with STZ and kept normoglycemic using exogenous insulin (STZ/IN), as well as in aging animals, two seemingly distinct beta-cell precursors were detected in islets [70]. These cells were characterized by the expression of Glut-2 and Pdx1/somatostatin, respectively. In RipCreER and Z/AP reporter mice [45] that label insulin+ cells by placent alcaline phosphatase (PLAP) and allow identification of putative precursor cells, the islets of aging and STZ/IN-treated mice contained beta-cell precursors expressing either Pdx1 or MafB [28]. These findings contrast with the beta-cell replication described earlier [45], and were attributed to differences in immunohistochemical techniques [28]. However, the source of these putative precursor cells remains unclear and, as the authors pointed out, they may also have a ductal origin. Interestingly, Glut-2-positive cells were also detected in the PANC-ATTAC mouse model characterized by beta-cell injury provoked by the activation of caspase 8-mediated apoptosis, as well as in the pancreatic duct of PDL-treated rats [15,75].
It is worth noticing that the Mafb+ cells, probably representing alpha-cells, detected in the islets of STZ/IN-treated or aging mice [28], are reminiscent of glucagon+ cells that spontaneously convert to beta-cells, following diphtheria toxin-mediated beta-cell depletion [8]. In both studies mice were treated with insulin to counter hyperglycemia and allow survival [8,28]. It is conceivable that the Mafb- or glucagon-marked cells contributing to beta-cell replenishment in these mice may derive from the duct epithelium, not excluding that intra-islet precursor cells may exist as well. Duct-derived endocrine cell neogenesis requires the reactivation of Ngn3 in the duct epithelium following pancreatic duct ligation or forced expression of Pax4 in alpha-cells [19,21]. Hence, duct-derived progenitors that differentiate into hormone producing cells may migrate in order to expand that beta-cell pool or, alternatively, form new islets adjacent to the duct epithelium.

5. Reprogramming acinar cells into beta-cells

As the most abundant cell type in pancreas, acinar cells are considered as a rich supply for generating beta-cells [80]. Culturing the acinar cancer cell line AR42J in the presence of betacellulin, activin or glucagon-like peptide, was found to induce insulin or glucagon production [81–83]. Dexamethasone treatment of duct-ligated rat pancreas provoked acino-ductal transdifferentiation and revealed an intermediate cell type coexpressing both acinar and duct markers [84]. The currently most successful approach consists in supplementing rat acinar cell culture with the cytokines epidermal growth factor (EGF) and leukemia inhibitory factor (LIF) to generate functional beta-cells that normalized hyperglycemia in immune-incompetent diabetic mice [85]. This transdifferentiation process was found to pass through an intermediary cell type that expresses both duct- and beta-cell markers [85], such results being confirmed by non-genetic lineage tracing [86]. Acinar- to beta-cell reprogramming uses Notch signaling as gatekeeper [86] and requires both Ngn3 expression and signaling through the JAK/STAT pathway [87]. The notion of acinar- to beta-cell differentiation was further supported by genetic lineage tracing in suspension cultures of adult pancreatic exocrine cells isolated from transgenic mice expressing the ROSA26-eCFP, infected with recombinant adenoviruses expressing Cre under the control of the promoter of either amylase-2 or elastase-1 in cell cultures supplemented with EGF and nicotinamide [88]. Furthermore, in vitro culture of pancreatic explants isolated from transgenic mice expressing TGF-alpha under the control of the metallothionein promoter, revealed that acinar- to duct transdifferentiation occurs through a dedifferentiated nestin-positive intermediate, in an EGFR-dependent manner [89]. It has been speculated that EGF activation in pancreatic exocrine cell cultures could be triggered by cell dissociation and that exogenous EGF might enhance cell survival [88].

In addition, transgenic mice expressing IFN-gamma under the control of the insulin promoter countered STZ-mediated beta-cell depletion through the budding of newly formed islets from ducts, with acinar cells as putative precursors [90]. In contrast, during regeneration of the mouse exocrine pancreas after caerulein-induced pancreatitis, acinar cell dedifferentiation was observed without further redifferentiation into duct cells [91]. Replenishment of the exocrine tissue in caerulein-mediated pancreatitis depended on the Notch signaling pathway and was mediated by repression of beta-catenin signaling pathway [92]. In transgenic mice expressing the tamoxifen-inducible Cre recombinase (CreERT2) under the control of the acinar-specific promoter elastase I, and crossed with Rosa26LacZ mice, lineage tracing was performed in three models with pancreas injury, including PPX, PDL and caerulein-induced pancreatitis, but no evidence for the contribution of acinar cells to islet neogenesis was found [93]. Following PPX, self-replication of preexisting acinar cells was the predominant mechanism involved in regeneration of the newly formed acinar tissue [94]. This indicates that the capacity of adult acinar cells to transdifferentiate into endocrine cells in vivo is still a matter of debate and that more challenging studies are needed. On the other hand, the forced co-expression of Pdx1, Ngn3 and Mafa in acinar cells promoted the formation of insulin-producing beta-cells in vivo by direct conversion rather than dedifferentiation [95]. The reprogramming of acinar cells by the forced expression of transcription factors suggests that the transdifferentiation of acinar to endocrine cells is under the control of a repressive mechanism, like Notch signaling, in the normal pancreas. Accordingly, inhibition of Notch1 signaling results in a more efficient acinar- to beta-cell conversion [86].

Finally, the centroacinar and terminal duct cells of the pancreas are not well defined and their molecular characteristics poorly established [96,97]. Only few studies have suggested that these cells have the capacity to actively proliferate in different injury models, including PPX, or treatment with caerulein or STZ [18,98,99]. However, it is not clear whether the centroacinar and terminal duct (CA/TD) cells consist of distinct cell types or are functionally equivalent. Recently, these cells were characterized by immunohistochemistry and were found to display high levels of ALDH1 enzymatic activity [100] enabling their isolation by FACS. Isolated CA/TD cells are able to differentiate into endocrine and exocrine cell types in vitro. Following caerulein administration to PPX, self-replication of preexisting acinar cells was the predominant mechanism involved in regeneration of the newly formed acinar tissue [94]. This indicates that the capacity of adult acinar cells to transdifferentiate into endocrine cells in vivo is still a matter of debate and that more challenging studies are needed. On the other hand, the forced co-expression of Pdx1, Ngn3 and Mafa in acinar cells promoted the formation of insulin-producing beta-cells in vivo by direct conversion rather than dedifferentiation [95]. The reprogramming of acinar cells by the forced expression of transcription factors suggests that the transdifferentiation of acinar to endocrine cells is under the control of a repressive mechanism, like Notch signaling, in the normal pancreas. Accordingly, inhibition of Notch1 signaling results in a more efficient acinar- to beta-cell conversion [86].

Finally, the centroacinar and terminal duct cells of the pancreas are not well defined and their molecular characteristics poorly established [96,97]. Only few studies have suggested that these cells have the capacity to actively proliferate in different injury models, including PPX, or treatment with caerulein or STZ [18,98,99]. However, it is not clear whether the centroacinar and terminal duct (CA/TD) cells consist of distinct cell types or are functionally equivalent. Recently, these cells were characterized by immunohistochemistry and were found to display high levels of ALDH1 enzymatic activity [100] enabling their isolation by FACS. Isolated CA/TD cells are able to differentiate into endocrine and exocrine cell types in vitro. Following caerulein administration to

![Fig. 1. Beta-cell development and regeneration. Schematics representing various roadmaps leading to the generation of functional insulin-producing cells. During embryonic development, beta-cells are generated from Ngn3+ progenitors. Moreover, beta-cells have the capacity to undergo self-replication to expand the beta-cell mass. This occurs during development, pregnancy, and following injury. Findings from several independent studies, using various pancreas injury models, are consistent with the idea that stem/progenitor cells do exist in the adult pancreas. Several sources of facultative stem/progenitor cells were suggested and are depicted: duct epithelium, acinar cells, centroacinar (CA)/terminal duct (TD), and intra-islet progenitors. Glucagon+, Pdx1+, and Ngn3+ were often found in the duct lining, suggesting that this may be a site where stem/progenitor cells at least transiently reside.](image-url)
induce pancreatitis, ALDH1+ CA/TD cells were found expanded, as compared to controls, suggesting that CA/TD cells possess progenitor cell characteristics [100]. Along the same line, lineage tracing of Bmi1+ cells identified a self-renewing pancreatic acinar cell population capable of maintaining pancreatic organ homeostasis [101]. Further studies are needed to examine whether CA/TD cells are able to contribute to the endocrine cell compartment, as previously suggested [18,99] (see Fig. 1).

6. Conclusions

Beta-cell proliferation clearly appears as the fundamental mechanism involved for beta-cell turn-over. The induction of beta-cells in vitro to generate sufficient numbers of cells for transplantation would be an interesting alternative if at least the expanded beta-cell mass would remain glucose responsive. A similar approach in vivo should carefully take the risk of tumor formation, such as insulinomas, into account.

Islet transplantation demonstrated that stem cell-based therapy could represent a realistic option for the treatment of diabetes. Hence, the current islet shortage may be compensated in the future by the generation of insulin-producing beta-cells from pancreatic non-beta-cells, beta-cell progenitors or embryonic stem cells. Besides embryonic stem cells, it is now well accepted that the injured adult pancreas has the capacity to regenerate new beta-cells: several independent studies in various animal models of beta-cell injury provided strong evidences for the existence of facultative stem cells that are able to give rise to functional beta-cells. The source of such cells still is subject of controversial discussion. A molecular analysis of the current models is required to identify the factors implicated in the activation of such cells. Gaining further insights into the molecular mechanisms underlying regeneration processes may disclose the different cell sources that are implicated in endocrine cell neogenesis. It should be outlined that, depending on the type of pancreatic injury, different progenitor cells might be activated. In this context, it is of high interest to define the factors implicated in the activation of such cells. Gaining further insights into the molecular mechanisms underlying regeneration processes may disclose the different cell sources that are implicated in endocrine cell neogenesis. It should be outlined that, depending on the type of pancreatic injury, different progenitor cells might be activated. In this context, it is of high interest to define the factors implicated in the activation of such cells.

Nevertheless, the hunting for tools that activate stem cells in vivo, or induce the transdifferentiation of non-beta hormone-producing cells, such as alpha-cells, into functional beta-cells, is now open. Future efforts should focus on the identification of markers for facultative stem cells in the injured pancreas and examine whether such molecules also do exist in the human pancreas.

Acknowledgements

Due to space constrains we apologize to many colleagues in the field whose work we could not cite. The authors are supported by the Max-Planck Society, the Bundesministerium für Bildung und Forschung (BMBF 01KU0906), the Dr. H. Storz and Alte Leipziger foundation (AM), the Juvenile Diabetes Research Foundation (26-2008-639), the INSEREN AVENIR program, the INSERM, the Fondation pour la Recherche Médicale (DRC20091217179), the Agence Nationale de la Recherche (2009 GENO 105 01), the Schlumberger Foundation (PC), the NIH Beta Cell Biology Consortium (DK05US19DK072495 – AM, PC, HH), the Research Council of Vrije Universiteit Brussel, JDRF (XX and HH), the European Federation for the Study of Diabetes, the National Fund for Scientific Research-Flanders, and the European Union (HH).

References

Rankin MM, Kushner JA. Adaptive beta-cell proliferation is severely restricted


Kushner JA, Ciemerych MA, Sicinska E, Wartschow LM, Teta M, Long SY, et

Georgia S, Bhushan A. Beta cell replication is the primary mechanism for

Lee YC, Nielsen JH. Regulation of beta cell replication. Mol Cell Endocrinol


Teta M, Long SY, Wartschow LM, Rankin MM, Kushner JA. Very slow turnover


Heit JJ, Karnik SK, Kim SK. Intrinsic regulators of pancreatic beta-cell prolifera-


Marzo N, Mora C, Fabregat ME, Martin J, Usac EF, Franco C, et al. Pancreatic islets from cyclin-dependent kinase 4/R24C (Cdk4) knockin mice have significantly increased beta cell mass and are physiologically functional, indicating that Cdk4 is a potential target for pancreatic beta cell mass regeneration in Type 1 diabetes. Diabetologia 2004;47:686–94.


Cozar-Castellano, Tanaka KK, Bottino R, Balamurugan AN, Stewart AF. Induc-


Dor Y, Melton DA. Facultative endocrine progenitor cells in the adult pancreas.

Guz Y, Naris I, Teitelman G. Regeneration of pancreatic beta cells from intra-


